Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/23020
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study
Author: Pittman, K.
Olver, I.
Koczwara, B.
Kotasek, D.
Patterson, W.
Keefe, D.
Karapetis, C.
Parnis, F.
Moldovan, S.
Yeend, S.
Price, T.
Citation: British Journal of Cancer, 2006; 95(10):1309-1313
Publisher: Nature Publishing Group
Issue Date: 2006
ISSN: 0007-0920
1532-1827
Statement of
Responsibility: 
K B Pittman, I N Olver, B Koczwara, D Kotasek, W K Patterson, D M Keefe, C S Karapetis, F X Parnis, S Moldovan, S J Yeend and T J Price for the Adelaide Cancer Trials and Education Collaborative (ACTEC)
Abstract: Cancer of unknown primary site (CUP) represents up to 5% of all cancer diagnoses and is associated with poor survival. We have performed a prospective multicentre phase 2 trial to evaluate efficacy and toxicity of the combination of gemcitabine (G) and carboplatin (C) for patients with CUP. Patients with histologically confirmed metastatic carcinoma in which the primary site of cancer was not evident after prospectively designated investigation and who had ECOG performance status 0–2 were treated with G 1000 mg m<sup>−2</sup> intravenously (i.v.) days 1 and 8, and C AUC 5 i.v. on day 8 every 3 weeks to a maximum of nine cycles. The primary end points were response rate, and toxicity, with secondary end points of progression-free survival and overall survival. Fifty-one (23 male, 27 female) patients were enrolled (one patient ineligible), with a median age of 69 years (range 41–83 years). Fifty patients were evaluable for toxicity and 46 patients were evaluable for efficacy. The overall response rate to the GC regimen was 30.5%. With a median follow-up of 24 months, the median progression-free survival was 18 weeks (4.2 months) and the median overall survival was 34 weeks (7.8 months). The frequency of grade 3 or 4 toxicity was low. Nausea/vomiting was the most common side effect, but was usually only mild in severity. Uncomplicated neutropenia (14%), thrombocytopenia (10%) and anaemia (8%) were the most common causes of grade 3–4 toxicity. The regimen was very well tolerated, particularly in the elderly. The GC regimen is an active regimen in CUP with excellent tolerability and should be considered particularly for elderly patients with CUP
Keywords: cooperative oncology group; combination; cisplatin; chemotherapy; paclitaxel; adenocarcinoma
Rights: © 2006 Cancer Research UK
RMID: 0020061697
DOI: 10.1038/sj.bjc.6603440
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_23020.pdfPublished version109.99 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.